 The purpose of this study is to determine if dose escalation of the rituximab-ICE RICEesc program can improve the overall response rate of patients with primary refractory or poor risk relapsed aggressive B cell lymphoma. R-ICEesc will be administered for 2 cycles with peripheral blood progenitor cells PBPCs collected after cycle 2. 